Prexton Therapeutics
acquired by LundbeckCopenhagen, DK · 3 known investors
Lundbeck is a global pharmaceutical company specializing in researching, developing, manufacturing, and commercializing medications for brain diseases and neurological conditions. The company serves patients and healthcare providers worldwide across the neuroscience field.
Investors · 3
In the news
- M&A of the Year: Prexton Therapeutics - Global Venturingglobalventuring.com · 2019
- Newcomer Appello raises $10.5M for new Vanderbilt Parkinson’s drug | Fierce Biotechfiercebiotech.com · 2018
- Prexton Acquired by Lundbeck for up to €905m. – Seroba Lifesciencesserobavc.com · 2018
- Serono spinout raises €29M for phase 2 Parkinson’s trials | Fierce Biotechfiercebiotech.com · 2017
- Prexton Therapeutics raises €8.7 million ($10 million) in a Series A round – Ysios Capitalysioscapital.com · 2015
- Prexton Therapeutics Raises €8.7M in Series A Funding - FinSMEsfinsmes.com · 2015